EAU 2023 | Active surveillance for Gleason grade 2 prostate cancer

Juan Gómez Rivas, MD, PhD, Clínico San Carlos University Hospital, Madrid, Spain, discusses active surveillance for Gleason grade two (GG2) prostate cancer. Active surveillance was the only treatment option for GG1 tumors, however a select group of patients with GG2 prostate cancer also benefit from this strategy. Active surveillance helps to preserve quality of life and avoid overtreatment. Dr Rivas describes the eligibility criteria for selecting patients with GG2 prostate for active surveillance, including a Gleason pattern 4 lower than 10%, a low number of cores, a PSA level below 10 and negative MRI. This interview took place at the EAU congress in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.